Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.46 |
| ▸ | JAK1 | P23458 | 19/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | ATP4A | P20648 | 1/20 | 0.37 |
| ▸ | ATP4B | P51164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16102315 | 1.00 | JAK2 (0.46) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL16103072 | 1.00 | JAK2 (0.46) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL18084498 | 1.00 | JAK2 (0.46) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL16121007 | 1.00 | JAK2 (0.46) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL16121008 | 0.95 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL16121108 | 0.95 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL16103414 | 0.95 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL16103083 | 0.95 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL16102111 | 0.95 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ATP4A | |
| SCHEMBL16102999 | 0.95 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957265-B2 | N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160272633-A1 | N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272633-A1 | N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.